Cover Image

Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications: review article

Bortezomib (BTZ) is a first-in-class reversible and selective proteasome inhibitor. It inhibits the ubiquitin proteasome pathway that leads to the degradation of many intracellular proteins. Initially, BTZ was FDA approved for the treatment of refractory or relapsed multiple myeloma (MM) in 2003. La...

Full description

Saved in:
Bibliographic Details
Main Authors: AlWahsh, Mohammad (Author) , Farhat, Joviana (Author) , Talhouni, Shahd (Author) , Hamadneh, Lama (Author) , Hergenröder, Roland (Author)
Format: Article (Journal)
Language:English
Published: January 16, 2023
In: EXCLI journal
Year: 2023, Volume: 22, Pages: 146-168
ISSN:1611-2156
DOI:10.17179/excli2022-5653
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.17179/excli2022-5653
Verlag, kostenfrei, Volltext: https://www.excli.de/index.php/excli/article/view/5653
Get full text
Author Notes:Mohammad Alwahsh, Joviana Farhat, Shahd Talhouni, Lama Hamadneh, Roland Hergenröder
Description
Summary:Bortezomib (BTZ) is a first-in-class reversible and selective proteasome inhibitor. It inhibits the ubiquitin proteasome pathway that leads to the degradation of many intracellular proteins. Initially, BTZ was FDA approved for the treatment of refractory or relapsed multiple myeloma (MM) in 2003. Later, its usage was approved for patients with previously untreated MM. In 2006, BTZ was approved for the treatment of relapsed or refractory Mantle Cell Lymphoma (MCL) and, in 2014, for previously untreated MCL. BTZ has been extensively studied either alone or in combination with other drugs for the treatment of different liquid tumors especially in MM. However, limited data evaluated the efficacy and safety of using BTZ in patients with solid tumors. In this review, we will discuss the advanced and novel mechanisms of action of BTZ documented in MM, solid tumors and liquid tumors. Moreover, we will shed the light on the newly discovered pharmacological effects of BTZ in other prevalent diseases.
Item Description:Gesehen am 03.06.2024
Physical Description:Online Resource
ISSN:1611-2156
DOI:10.17179/excli2022-5653

Similar Items